Methods and compounds for eliminating immune responses to therapeutic agents

US11787849B2 · kind B2 · utility

Assignee

• IMCYSE SA · BE

Inventors

• Jean-Marie Saint-Remy · Grez-Doiceau, BE
• Luc Vander Elst · Obaix, BE
• Vincent Carlier · Énines, BE

Key dates

• Filing date: Sep 23, 2016
• Grant date: Oct 17, 2023
• Expiry date: May 30, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/40
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention describes kit of parts of polypeptides comprising: a) a peptide comprising: a1) an MHC class II T cell epitope or a CD1 d-restricted NKT cell epitope, and a2) immediately adjacent to said epitope or separated by at most 7 amino acids from said epitope a [CST]-X(2)-C [SEQ ID NO:7] or C-X(2)-[CST] [SEQ ID NO:8] oxidoreductase motif sequence, and b) a polypeptide comprising: b1) a therapeutic protein and b2) the epitope defined in a1), wherein the epitope sequence is a sequence which differs from the sequence of the protein of b1). The therapeutic protein, in combination with the peptide, is used to prevent an immune response against the therapeutic protein.